The evidence leans constructive4 supporting, 2 against, 0 worth knowing
Supporting
trading 18% above its 200-day average
matches the market's strongest stocks, which has beaten the market by +0.37 points over 20 sessions across 48,607 past signals
3 independent kinds of evidence agree today, which is uncommon
revenue grew 9% year on year in the quarter ending 2026-06-30
Against
down 2% over twelve months
net margin has narrowed from 16.9% to 16.0% across four quarters
Worth knowing
nothing the data supports either way
What would change this read: a close below 201, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
How it has performed
price return over each window, measured against zero
What the scans say today
5 of 47 matched on 2026-08-21
JAGSNPHARM matches 5 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
JAGSNPHARM trades at 34× trailing earnings, above its median of 28× over this window — 23% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 9% against the same quarter a year earlier
profit rose 22% year on year
net margin widened from 13.6% to 16.0%
Going against it
revenue rose in 1 of the last 4 quarters
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · standalone
82
18
13
2.00
16.0%
Q4 FY26
2026-03-31 · standalone
64
12
9
1.25
13.6%
Q3 FY26
2025-12-31 · standalone
73
15
11
1.67
15.0%
Q2 FY26
2025-09-30 · standalone
74
17
13
1.88
16.9%
Q1 FY26
2025-06-30 · standalone
76
14
11
1.60
14.3%
Q4 FY25
2025-03-31 · standalone
59
9
7
0.98
11.2%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+3.6%
Versus 200-day average+17.8%
Below 52-week high-5.4%
Above 52-week low+46.9%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)51.3
Higher closes in last 53 of 5
Six-month return+40.25%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.